T1期高级别尿路上皮癌的治疗进展

doi:10.11904/j.issn.1002-3070.2022.03.017

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (3): 283-287.doi: 10.11904/j.issn.1002-3070.2022.03.017

T1期高级别尿路上皮癌的治疗进展

王雷雷综述, 陈辉审校

哈尔滨医科大学附属肿瘤医院泌尿外科(哈尔滨 150081)

收稿日期:2021-09-24 修回日期:2021-12-09 出版日期:2022-06-28 发布日期:2022-06-28
通讯作者: 陈辉,E-mail:13603612355@139.com
作者简介:王雷雷,男,(1996-),硕士研究生,从事泌尿系肿瘤相关的研究。

Progress in the treatment of T1 high-grade urothelial carcinoma

WANG Leilei, CHEN Hui

Department of Urology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2021-09-24 Revised:2021-12-09 Online:2022-06-28 Published:2022-06-28

摘要/Abstract

摘要： 膀胱癌是泌尿系统常见的肿瘤,其中90%以上的膀胱癌病理类型为尿路上皮癌,按照肿瘤浸润深度可分为非肌层浸润性尿路上皮癌(Non muscle invasive bladder cancer,NMIBC)和肌层浸润性尿路上皮癌。NMIBC主要是指肿瘤侵及固有层(T1)、粘膜层(Ta)和原位癌(Tis),其预后较好。其中Ta、T1期肿瘤占大多数,两者虽然都属于NMIBC,但生物学特性不同,由于固有层血管和淋巴管丰富,故T1期肿瘤较容易发生扩散和复发。本文将重点针对T1期高级别尿路上皮癌的各种治疗方式,包括手术治疗、介入治疗、药物化疗和免疫治疗等方面做一综述,特别探讨了如何利用手术治疗方式以及手术治疗联合化疗提高治疗效果,减少复发,提高生存时间。

关键词: T1期高级别尿路上皮癌, 膀胱灌注, 经尿道膀胱肿瘤电切术

Abstract: Bladder cancer is a common tumor of the urinary system.More than 90% of bladder cancers are urothelial carcinoma.According to the depth of tumor invasion,it can be divided into non-muscle invasive urothelial carcinoma(NMIBC)and muscular invasive urothelial carcinoma.NMIBC has a good prognosis,which mainly refers to tumor invasion into lamina propria(T1),mucosal layer(Ta)and carcinoma in situ(Tis).Among them,Ta and T1 stage tumors account for the majority.Although both belong to NMIBC,their biological characteristics are different from each other.Because of the abundance of blood vessels and lymphatic vessels in lamina propria,T1 stage tumors are more prone to spread and recurrence.This article will focus on different treatment methods for T1 high-grade urothelial carcinoma,including surgical treatment,interventional therapy,drug chemotherapy,immunotherapy,etc.,and especially discusses how to use surgical treatment and surgical treatment combined with chemotherapy to improve the treatment effect,reduce recurrence and improve the survival time.

Key words: T1 high-grade urothelial carcinoma, Bladder perfusion, Transurethral resection of bladder tumor

中图分类号:

R737.14

王雷雷, 陈辉. T1期高级别尿路上皮癌的治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 283-287.

WANG Leilei, CHEN Hui. Progress in the treatment of T1 high-grade urothelial carcinoma[J]. Journal of Practical Oncology, 2022, 36(3): 283-287.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/283

参考文献

1 DeGeorge KC,Holt HR,Hodges SC.Bladder cancer:diagnosis and treatment[J].Am Fam Physician,2017,96(8):507-514.
2 Babjuk M,Burger M,Compérat EM,et al.European association of urology guidelines on non-muscle-invasive bladder cancer(TaT1 and Carcinoma In Situ)-2019 update[J].Eur Urol,2019,76(5):639-657.
3 Malmström PU,Agrawal S,Bläckberg M,et al.Non-muscle-invasive bladder cancer:a vision for the future[J].Scand J Urol,2017,51(2):87-94.
4 Mannas MP,Lee T,Nykopp TK,et al.A risk-stratified approach to the management of high-grade T1 bladder cancer[J].Curr Opin Urol,2018,28(6):563-569.
5 Srougi V,Reis ST,Viana N,et al.Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer[J].World J Urol,2021,39(2):453-459.
6 Fujii Y.Prediction models for progression of non-muscle-invasive bladder cancer:a review[J].Int J Urol,2018,25(3):212-218.
7 Gregg JR,McCormick B,Wang L,et al.Short term complications from transurethral resection of bladder tumor[J].Can J Urol,2016,23(2):8198-8203.
8 Krajewski W,Moschini M,Nowak Ł,et al.Restaging transurethral resection of bladder tumours after BCG immunotherapy induction in patients with T1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit[J].J Clin Med,2020,9(10):3306.
9 Schraml J,Silva JDC,Babjuk M.Current concept of transurethral resection of bladder cancer:from re-transurethral resection of bladder cancer to enbloc resection[J].Curr Opin Urol,2018,28(6):591-597.
10 Steinberg RL,Thomas LJ,O′Donnell MA.Combination intravesical chemotherapy for non-muscle-invasive bladder cancer[J].Eur Urol Focus,2018,4(4):503-505.
11 Morizane S,Honda M,Ueki M,et al.New technique of transurethral en bloc resection of bladder tumor with a flexible cystoscope and endoscopic submucosal dissection devices for the gastrointestinal tract[J].Int J Urol,2020,27(3):268-269.
12 Dug H,Jagodić S,Ahmetovi-Dug J,et al.Predicting recurrence of non-muscle-invasive bladder cancer after transurethral resection[J].Med Glas(Zenica),2016,13(1):56-61.
13 Chang DTS,Picardo A.Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer:the Western Australian experience[J].Bladder(San Franc),2020,7(2):e42.
14 Zhou W,Wang W,Wu W,et al.Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer A retrospective single-center study of 251 patients[J].BMC Urol,2020,20(1):30.
15 Lyons MD,Smith AB.Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer[J].Urol Oncol,2016,34(6):262-270.
16 Zeng XT,Liu TZ,Gong K,et al.The BPSC:A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population[J].J Evid Based Med,2018,11(1):64-67.
17 Raby SEM,Choudhury A.Radiotherapy for high-grade T1 bladder cancer[J].Eur Urol Focus,2018,4(4):506-508.
18 Li R,Li Y,Song J,et al.Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer:a systematic review and meta-analysis of randomized controlled trial[J].BMC Urol,2020,20(1):97.
19 Rose TL,Milowsky MI.Improving systemic chemotherapy for bladder cancer[J].Curr Oncol Rep,2016,18(5):27.
20 Haroon UM,Galvin DJ.Letter to the editor regarding the article "Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors"[J].World J Urol,2020,38(5):1343.
21 Peycelon M,Szymanski KM,Francesca Monn M,et al.Adherence with bladder irrigation following augmentation[J].J Pediatr Urol,2020,16(1):33.
22 Xia Y,Kang TW,Jung YD,et al.Sulforaphane inhibits nonmuscle invasive bladder cancer cells proliferation through suppression of HIF-1α-Mediated glycolysis in hypoxia[J].J Agric Food Chem,2019,67(28):7844-7854.
23 Efiloğlu Ö,Bayrak Ö,Turan T,et al.Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.Quimioterapia intravesical térmica como tratamiento adyuvante en pacientes de cáncer de vejiga alto riesgo no-musculoinvasivos[J].Arch Esp Urol,2021,74(9):875-882.
24 Han J,Gu X,Li Y,et al.Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect[J].Biomed Pharmacother,2020,129:110393.
25 Veeratterapillay R,Heer R,Johnson MI,et al.High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage[J].Curr Urol Rep,2016,17(9):68.
26 Lammers RJ,Witjes JA,Inman BA,et al.The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer:a systematic review[J].Eur Urol,2011,60(1):81-93.
27 Aoun F,Rassy EE,Assi T,et al.Advances in urothelial bladder cancer immunotherapy,dawn of a new age of treatment[J].Immunotherapy,2017,9(5):451-460.
28 Butt SU,Malik L.Role of immunotherapy in bladder cancer:past,present and future[J].Cancer Chemother Pharmacol,2018,81(4):629-645.

[1]	武洪林,齐玉华,王志超,徐磊,戴洪双,乔忠杰. 静脉应用维库溴铵预防膀胱侧壁肿瘤电切术闭孔神经反射的研究[J]. 实用肿瘤学杂志, 2013, 27(5): 417-420.
[2]	李彦生;李长福;陈永胜. 吡柔比星、丝裂霉素和羟基喜树碱抑制膀胱癌最佳组合的研究[J]. 实用肿瘤学杂志, 2007, 21(04): 353-355.

T1期高级别尿路上皮癌的治疗进展

Progress in the treatment of T1 high-grade urothelial carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价